HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A Whole Blood Assay for AR-V7 and ARv567es in Patients with Prostate Cancer.

AbstractPURPOSE:
Most prostate cancer mortality can be attributed to metastatic castration resistant prostate cancer, an advanced stage that remains incurable despite recent advances. The AR (androgen receptor) signaling axis remains active in castration resistant prostate cancer. Recent studies suggest that expression of the AR-V (AR splice variant) AR-V7 may underlie resistance to abiraterone and enzalutamide. However, controversy exists over the optimal assay. Our objective was to develop a fast and sensitive assay for AR-Vs in patients.
MATERIALS AND METHODS:
Two approaches were assessed in this study. The first approach was based on depletion of leukocytes and the second one used RNA purified directly from whole blood preserved in PAXgene® tubes. Transcript expression was analyzed by quantitative reverse transcription-polymerase chain reaction.
RESULTS:
Through a side-by-side comparison we found that the whole blood approach was suitable to detect AR-Vs. The specificity of the assay was corroborated in a cancer-free cohort. Using the PAXgene assay samples from a cohort of 46 patients with castration resistant prostate cancer were analyzed. Overall, AR-V7 and ARv567es were detected in 67.53% and 29.87% of samples, respectively. Statistical analysis revealed a strong association of AR-V positivity with a history of second line hormonal therapies.
CONCLUSIONS:
To our knowledge this is the first study to demonstrate that PAXgene preserved whole blood can be used to obtain clinically relevant information regarding the expression of 2 AR-Vs. These data on a castration resistant prostate cancer cohort support a role for AR-Vs in resistance to therapies targeting the AR ligand-binding domain.
AuthorsXichun Liu, Elisa Ledet, Dongying Li, Ary Dotiwala, Allie Steinberger, Allison Feibus, Jianzhuo Li, Yanfeng Qi, Jonathan Silberstein, Benjamin Lee, Yan Dong, Oliver Sartor, Haitao Zhang
JournalThe Journal of urology (J Urol) Vol. 196 Issue 6 Pg. 1758-1763 (12 2016) ISSN: 1527-3792 [Electronic] United States
PMID27449259 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2016 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Chemical References
  • AR protein, human
  • Protein Isoforms
  • Receptors, Androgen
Topics
  • Adult
  • Aged
  • Cross-Sectional Studies
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms (blood)
  • Prostatic Neoplasms, Castration-Resistant (blood, diagnosis)
  • Protein Isoforms (blood)
  • Receptors, Androgen (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: